Rheumatoid Arthritis
Conditions
Interventions
None listed
Sponsors
Hirosaki University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients between 20 and 75 years of age who have been diagnosed with rheumatoid arthritis, according to the 2010 ACR/EULAR classification criteria. 2.Patients have no effects or not enough effects from one csDMARDs or more and who bDMARDs-naiive (DAS 28>3.2 or SDAI>11 or CDAI>10 at registration). 3.Patients were started Abatacept dose by a decision from physicians. 4.Patients who provide written consent form to participate in this study after full explanation of the study.
Exclusion criteria
Exclusion criteria: 1.Patients who are suffering from severe infectious disease. 2.Patients with lymphocytes less than 500/microL and high levels of beta-D glucan 3.Patients who are infected EB virus or HBV 4.Patients who are unsuitable to participate in this study by attending physicians.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| -Improvement rate of PDUS score in Abatacept dose 8 weeks later | — |
Secondary
| Measure | Time frame |
|---|---|
| -Improvement rate of PDUS score in Abatacept dose 24 and 48 weeks later -Relevance between the improvement rate of pain score and PDUS score in Abatacept dose 0, 2, 4, 8, 24, 48 weeks later -Transition of disease activity in Abatacept dose 0, 2, 4, 8, 24, 48 weeks later -Relevance between ACPA, RF, Cytokine expression levels and improvement rate of PDUS score, pain score, disease activity | — |
Countries
Japan
Contacts
Public ContactHirotake Sakuraba
Hirosaki University Graduate School of Medicine Department of Gastroenterology and Hematology
Outcome results
None listed